VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 05, 2008) - Pacgen Biopharmaceuticals Corporation (“Pacgen”) (TSX VENTURE: PGA) today announced positive results from its Phase IIb dose-ranging trial of PAC-113, a novel anti-fungal drug candidate. The results demonstrated that PAC-113 is effective in the treatment of oral Candidiasis and compares favourably to the efficacy demonstrated by Nystatin, a current standard of care.
